The worldwide neurodegenerative disease market size was estimated at USD 40,125 million in 2021, and it is predicted to reach USD 53,275 million by 2030, recording a CAGR of 3.2% during the forecast period (2022–2030).
In most cases, neurodegenerative disorders are characterised by gradual nerve cell degeneration that can occur in a variety of locations across the body. Loss of memory and cognitive control are potential outcomes of a number of conditions, including Alzheimer's disease, Parkinson's disease, attention deficit hyperactivity disorder (ADHD), and amyotrophic lateral sclerosis (ALS).
Although there are very few diseases that can be cured, the pharmaceutical industry has developed a variety of treatments throughout the years that aim to alleviate the symptoms of neurodegenerative ailments.
Neurodegenerative disorders are a varied group of ailments defined by the gradual degradation of the function and structure of the central nervous system or peripheral nervous system. Neurodegenerative disorders, including Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, and Huntington's disease, have been rising globally. Thus, the growing burden of this condition is the key driver driving the market expansion, adding to it the expanding elderly population. According to NIH, nearly 1.2 million people in the United States will have Parkinson's disease by 2030. In the United States, it is the second most frequent neurodegenerative disorder.
Furthermore, according to Alzheimer's Disease International, more than 50 million adults with dementia globally in 2020. This number is anticipated to be more than double every two decades, reaching 82 million in 2030 and 152 million in 2050. Additionally, much of the increase will be in emerging countries. About 60% of persons with dementia reside in poor and middle-income nations, but by 2050, this will climb to 71%. The fastest rise in the senior population has happened in China, India, and South Asian and western Pacific countries. Thus, the growing burden of dementia is likely to enhance the market growth in the approaching years.
Latin America: 1983 million USD (2030 value); CAGR: 2.01%
The key factors for the development of the Latin America market for the treatment of neurodegenerative diseases are the rising incidence of neurological and Parkinson's diseases as well as the rapid growth in the geriatric population with longer life expectancies, which is more prone to many neurological diseases. A further factor contributing to the expansion of the market is the expanding awareness of the many treatment choices currently on the market. According to the Parkinson Foundation, Parkinson's disease is far more prevalent in males than it is in females. Males had roughly 1.55 times the chance of developing the condition as compared to women, which led to the discovery of a greater incidence in men. The majority of those who are afflicted with this condition are above the age of sixty.
Despite this, there is currently no treatment that may permanently reverse Parkinson's disease or any other neurological condition. Some of the symptoms of such disorders can be alleviated by the use of medication, in conjunction with other treatments such as exercise. Drugs such as the combination of levodopa therapy, dopamine agonists, cholinesterase inhibitors, and other medications are utilised in the treatment of the numerous symptoms that are connected with the condition. As of right now, the combination therapy with levodopa that is used to treat the motor symptoms of this condition is highly recommended since it is effective. Even COMT (catechol-o-methyl transferase) inhibitors are becoming more common when used in conjunction with co-therapeutic drugs to achieve optimal efficacy.
In addition, numerous developments in treatment approaches, such as the creation of neurostimulation tools, gene therapy, and procedures for neural transplantation, operate as other growth factors that are projected to have a beneficial influence on the industry. Significant advancements have been made in the infrastructure of the healthcare industry, and these have been coupled with extensive research and development (R&D) activities, which are supported by governments and organisations that are not-for-profit, in order to develop promising product portfolios.
The market for the treatment of neurodegenerative diseases is growing quickly in Latin America; however, this expansion is being slowed by the widespread availability of alternative therapies as well as the poor efficacy of the treatment choices. In addition, the pharmaceuticals may have a variety of undesirable consequences, which may impede market expansion in the years to come. Some drugs, for instance, come with the risk of developing impulsive and compulsive behaviours as potential side effects. The expansion of the market for the treatment of neurodegenerative diseases in Latin America will also be hampered by the fact that the patents on several important brand-name medications will soon expire.
The Latin America neurodegenerative disease market is segmented according to the kind of indication, the type of medicine, and the geography.
Parkinson's disease, Alzheimer's disease, multiple sclerosis, Huntington's disease, and other indication types make up the Latin America neurodegenerative diseases market. Various indication types include other neurodegenerative diseases. Multiple sclerosis was the most lucrative sector of the market in 2021, bringing in a total of USD 25,680 million in sales. It is anticipated that it would reach USD 29,360 million by the year 2030, recording a CAGR of 1.5% over the duration of the prediction.
The number of people living with multiple sclerosis has risen in every region of the world. It is anticipated that the overwhelming majority of multiple sclerosis cases throughout the world will drive market growth. In addition, another key growth aspect is the growing interest of businesses in the items that are in the pipeline, as well as the comprehensive product approvals. For example, in October 2019, the United States Food and Drug Administration granted approval for the treatment of relapsing forms of multiple sclerosis (MS) to Vumerity (diroximel fumarate), an oral fumarate formulation of the drug. This approval covers clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
In terms of geography, Brazil held the greatest portion of the Latin America neurodegenerative diseases market in 2022, followed by Argentina with a significant market share. The regional markets in these regions will be supported by factors such as the high awareness among the senior population, increasing research funding and grants, favourable government regulations, and a high prevalence of neurological illness. The World Health Organization (WHO) has reported that the number of fatalities caused by Parkinson's disease in Brazil has reached 3,980, which accounts for 0.38% of all deaths, and that a total of 240 incident cases of PD have been found. In the meanwhile, the gross incidence was recorded as 31.24 cases per 100,000 people, while the prevalence was 395 cases per 100,000 people in Mexico's population over the age of 40. According to the most recent available information, the ratio of males to females in the population of Mexico is 1.32.
The regional markets in Argentina, Mexico, Peru, and Columbia are anticipated to be driven by other reasons such as the rapidly rising population of elderly people, promising clinical treatments, and attractive reimbursement policies.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|